Change in Tissue Microbiome and Related Human Beta Defensin Levels Induced by Antibiotic Use in Bladder Carcinoma

Int J Mol Sci. 2024 Apr 22;25(8):4562. doi: 10.3390/ijms25084562.

Abstract

It is now generally accepted that the success of antitumor therapy can be impaired by concurrent antibiotic therapy, the presence of certain bacteria, and elevated defensin levels around the tumor tissue. The aim of our current investigation was to identify the underlying changes in microbiome and defensin levels in the tumor tissue induced by different antibiotics, as well as the duration of this modification. The microbiome of the tumor tissues was significantly different from that of healthy volunteers. Comparing only the tumor samples, no significant difference was confirmed between the untreated group and the group treated with antibiotics more than 3 months earlier. However, antibiotic treatment within 3 months of analysis resulted in a significantly modified microbiome composition. Irrespective of whether Fosfomycin, Fluoroquinolone or Beta-lactam treatment was used, the abundance of Bacteroides decreased, and Staphylococcus abundance increased. Large amounts of the genus Acinetobacter were observed in the Fluoroquinolone-treated group. Regardless of the antibiotic treatment, hBD1 expression of the tumor cells consistently doubled. The increase in hBD2 and hBD3 expression was the highest in the Beta-lactam treated group. Apparently, antibiotic treatment within 3 months of sample analysis induced microbiome changes and defensin expression levels, depending on the identity of the applied antibiotic.

Keywords: antibiotic treatment; bladder cancer; human beta defensins; tissue microbiome.

MeSH terms

  • Aged
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Female
  • Fluoroquinolones / pharmacology
  • Fluoroquinolones / therapeutic use
  • Fosfomycin / pharmacology
  • Fosfomycin / therapeutic use
  • Humans
  • Male
  • Microbiota* / drug effects
  • Middle Aged
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / metabolism
  • Urinary Bladder Neoplasms* / microbiology
  • beta-Defensins* / metabolism
  • beta-Lactams / pharmacology
  • beta-Lactams / therapeutic use

Substances

  • beta-Defensins
  • Anti-Bacterial Agents
  • Fosfomycin
  • Fluoroquinolones
  • beta-Lactams